Neil Ku­mar’s Bridge­Bio team locks in a $2.4B part­ner­ship as their next drug gets a snap re­view at the FDA

Bridge­Bio $BBIO is on a roll.

At the end of Feb­ru­ary, they won an ap­proval for their first drug, a ther­a­py used to treat ex­treme­ly rare cas­es of molyb­de­num co­fac­tor de­fi­cien­cy type A. In the mid­dle of the month, there was pos­i­tive proof-of-con­cept da­ta for an­oth­er one of its subs, Cal­ci­lytix, for ADH1.

And to­day they’re wrap­ping a busy, buzzy month with a $2.4 bil­lion al­liance to roll out their next drug in the US — in­fi­gra­tinib — which looks to be in the la­bel-writ­ing stage at the FDA as reg­u­la­tors set up a chip shot on a near-term ap­proval.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER